Aptus Capital Advisors LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 75.5% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 38,416 shares of the company’s stock after buying an additional 16,531 shares during the period. Aptus Capital Advisors LLC’s holdings in Johnson & Johnson were worth $5,037,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Tamarack Advisers LP acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $18,035,000. Orser Capital Management LLC grew its stake in shares of Johnson & Johnson by 44.2% during the fourth quarter. Orser Capital Management LLC now owns 1,875 shares of the company’s stock worth $272,000 after purchasing an additional 575 shares during the period. Exchange Traded Concepts LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $31,000. Arkfeld Wealth Strategies L.L.C. acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $536,000. Finally, SeaCrest Wealth Management LLC grew its stake in shares of Johnson & Johnson by 5.8% during the fourth quarter. SeaCrest Wealth Management LLC now owns 49,644 shares of the company’s stock worth $7,241,000 after purchasing an additional 2,718 shares during the period. 67.66% of the stock is owned by institutional investors.

JNJ has been the subject of a number of analyst reports. Stifel Nicolaus lifted their price objective on Johnson & Johnson from $140.00 to $155.00 and gave the stock a “hold” rating in a research note on Wednesday, April 15th. Bank of America raised Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $150.00 to $175.00 in a research note on Wednesday, April 22nd. Wells Fargo & Co raised Johnson & Johnson to a “hold” rating in a research note on Wednesday, April 22nd. Credit Suisse Group reaffirmed a “buy” rating and set a $161.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Finally, Raymond James lifted their target price on Johnson & Johnson from $153.00 to $157.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Four equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $163.47.

In other news, Director William D. Perez purchased 500 shares of the business’s stock in a transaction dated Friday, March 13th. The shares were bought at an average cost of $127.69 per share, for a total transaction of $63,845.00. Following the completion of the acquisition, the director now directly owns 16,030 shares in the company, valued at approximately $2,046,870.70. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.27% of the company’s stock.

JNJ stock opened at $144.37 on Friday. The business’s 50-day moving average price is $146.81 and its two-hundred day moving average price is $142.30. The company has a current ratio of 1.31, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41. The firm has a market cap of $386.52 billion, a PE ratio of 19.10, a P/E/G ratio of 3.19 and a beta of 0.71. Johnson & Johnson has a 1-year low of $109.16 and a 1-year high of $157.00.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 14th. The company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.03 by $0.27. The company had revenue of $20.69 billion for the quarter, compared to analyst estimates of $19.48 billion. Johnson & Johnson had a return on equity of 39.71% and a net margin of 24.47%. The company’s quarterly revenue was up 3.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.10 earnings per share. On average, analysts forecast that Johnson & Johnson will post 7.68 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a $1.01 dividend. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.80%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend is Friday, May 22nd. Johnson & Johnson’s payout ratio is 43.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: How to interpret Moving Average Convergence Divergence (MACD)

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.